{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T10:26:39Z","timestamp":1783592799982,"version":"3.55.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The value of radical prostatectomy (RP) in large volume and unresectable locally advanced prostate cancer (LAPC) or oligometastatic prostate cancer (OMPC) is largely unknown. This retrospective study aims to evaluate the conversion efficacy and safety profile of preoperative androgen deprivation therapy combined with docetaxel (A\u00a0+\u00a0D) in patients with large-volume (\u226560 mL) and initially unresectable LAPC or OMPC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Patients with LAPC or OMPC from three large tertiary medical centers (between April 2017 and October 2024) were included. Eligibility criteria included prostate volume \u226560 mL, unresectability, and an expected survival of more than 5\u00a0years, as confirmed by two senior urologists and one radiologist. All patients received preoperative A +\u00a0D therapy (\u22653 cycles), followed by reassessment for RP feasibility with multimodal therapy discussion. The primary endpoint was surgical conversion rate. Secondary endpoints included prostate-specific antigen (PSA) progression-free survival (PSA-PFS), overall survival (OS), PSA response rate, adverse events, pathological response, perioperative complications, urinary continence, and sexual function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Among 31 enrolled patients, the mean age was 67.71\u00a0\u00b1\u00a06.69\u00a0years, and 29 (93.55%) successfully underwent RP. The mean follow-up duration was 42.83\u00a0\u00b1\u00a023.58\u00a0months (up to October 2024). Median PSA-PFS was 49\u00a0months (95% CI: 24.20\u201373.79\u00a0months), and median OS was not reached. Hematologic toxicity was the most common adverse event during chemotherapy. After A +\u00a0D therapy, median prostate tumor volume decreased from 67.50 mL to 25.81 mL, and median PSA declined from 168 to 0.49\u00a0ng\/mL. After RP, 11 patients (37.93%) experienced a downgrade in Gleason score, and 14 patients (48.28%) experienced a downgrade in T-stage. Positive surgical margins were found in 11 patients (37.93%). Perioperative complications included blood transfusion (11.11%), rectal injury (3.70%), lymphorrhea (7.41%), and fever &gt;38.5\u00b0C (3.70%). The 1-year urinary continence rate was 89.66%, while 100% of patients experienced sexual dysfunction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Preliminary data suggest that preoperative A +\u00a0D therapy followed by RP may be integrated into multimodal management for large-volume, initially unresectable LAPC and OMPC, demonstrating promising conversion efficacy and clinical outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/js9.0000000000005040","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T13:00:10Z","timestamp":1773752410000},"page":"12856-12865","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Preoperative ADT combined with docetaxel for conversion therapy in large-volume and unresectable locally advanced or oligometastatic prostate cancer: a multicenter retrospective study (YHCG-001 study)"],"prefix":"10.1097","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5953-0067","authenticated-orcid":false,"given":"Xin","family":"Fei","sequence":"first","affiliation":[{"name":"Health Science Center, Ningbo University, Ningbo, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-Da","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The Affiliated Yangming Hospital of Ningbo University, Ningbo, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Peng","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Urology, Zhejiang Cancer Center, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Mingzhou Hospital, Ningbo, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Chao","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Urology, Zhejiang Cancer Center, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Feng","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Urology, the First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Long","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Urology, the First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Urology, the First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Urology, the First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Urology, the First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-Ya","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Radiology, the First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China"},{"name":"Yi-Huan Genitourinary Cancer Group, Ningbo, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da-Wei","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Radiology, the First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China"},{"name":"Yi-Huan Genitourinary Cancer Group, Ningbo, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Ying","family":"Wang","sequence":"additional","affiliation":[{"name":"Yi-Huan Genitourinary Cancer Group, Ningbo, Zhejiang, China"},{"name":"Department of Tissue Pathology, Ningbo Clinical Pathology Diagnosis Center, Ningbo, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zhao","sequence":"additional","affiliation":[{"name":"Yi-Huan Genitourinary Cancer Group, Ningbo, Zhejiang, China"},{"name":"Medical Department, the First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-Chun","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Mingzhou Hospital, Ningbo, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[{"name":"Yi-Huan Genitourinary Cancer Group, Ningbo, Zhejiang, China"},{"name":"Department of Urology, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zong-Ping","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, Zhejiang Cancer Center, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Hui","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Urology, the First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5350-0362","authenticated-orcid":false,"given":"Qi","family":"Ma","sequence":"additional","affiliation":[{"name":"Yi-Huan Genitourinary Cancer Group, Ningbo, Zhejiang, China"},{"name":"Comprehensive Genitourinary Cancer Center, the First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"R1-20260709","first-page":"229\u201363","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"Ca A Cancer J Clin"},{"key":"R3-20260709","doi-asserted-by":"crossref","first-page":"140\u201350","DOI":"10.6004\/jnccn.2024.0019","article-title":"NCCN guidelines\u00ae insights: prostate cancer, version 3.2024","volume":"22","author":"Schaeffer","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"R4-20260709","doi-asserted-by":"crossref","first-page":"199\u2013207","DOI":"10.1016\/j.radonc.2022.10.005","article-title":"Recommendations for radiation therapy in oligometastatic prostate cancer: an ESTRO-ACROP delphi consensus","volume":"176","author":"Zilli","year":"2022","journal-title":"Radiotherapy and Oncol"},{"key":"R5-20260709","doi-asserted-by":"crossref","first-page":"1080\u201387","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase IIIE3805CHAARTED trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J Clin Oncol"},{"key":"R6-20260709","doi-asserted-by":"crossref","first-page":"164\u201382","DOI":"10.1016\/j.eururo.2024.04.010","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. part II-2024 update: treatment of relapsing and metastatic prostate cancer","volume":"86","author":"Tilki","year":"2024","journal-title":"Europ Urol"},{"key":"R7-20260709","first-page":"519\u201325","article-title":"Combination of androgen deprivation therapy with radical local therapy versus androgen deprivation therapy alone for newly diagnosed oligometastatic prostate cancer: a phase II randomized controlled trial","volume":"5","author":"Dai","year":"2022","journal-title":"European Urol Oncol"},{"key":"R8-20260709","first-page":"100081","article-title":"Revised strengthening the reporting of cohort, cross-sectional and case-control studies in surgery (STROCSS) guideline: an update for the age of Artificial Intelligence","volume":"10","author":"Agha","year":"2025","journal-title":"Prem J Sci"},{"key":"R9-20260709","first-page":"100082","article-title":"Transparency in the reporting of Artificial INtelligence\u2013 the TITAN guideline","volume":"10","author":"Agha","year":"2025","journal-title":"Prem J Sci"},{"key":"R10-20260709","doi-asserted-by":"crossref","first-page":"896\u2013905","DOI":"10.1001\/jama.2018.0587","article-title":"Radical prostatectomy, external beam radiotherapy, or external beam radiotherapy with brachytherapy boost and disease progression and mortality in patients with gleason score 9-10 prostate cancer","volume":"319","author":"Kishan","year":"2018","journal-title":"Jama"},{"key":"R11-20260709","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12957-020-01824-9","article-title":"The efficacy and safety of radical prostatectomy and radiotherapy in high-risk prostate cancer: a systematic review and meta-analysis","volume":"18","author":"Wang","year":"2020","journal-title":"World J Surg Oncol"},{"key":"R12-20260709","first-page":"375\u201384","article-title":"Survival after radical prostatectomy versus radiation therapy in high-risk and very high-risk prostate cancer","volume":"207","author":"Chierigo","year":"2022","journal-title":"J Urol"},{"key":"R13-20260709","doi-asserted-by":"crossref","first-page":"215\u201324","DOI":"10.1016\/j.clgc.2014.01.010","article-title":"Radical prostatectomy or radiotherapy in high-risk prostate cancer: a systematic review and metaanalysis","volume":"12","author":"Petrelli","year":"2014","journal-title":"Clin Genitourinary Cancer"},{"key":"R14-20260709","first-page":"68\u201376","article-title":"The role of cytoreductive radical prostatectomy in the treatment of newly diagnosed low-volume metastatic prostate cancer. results from the local treatment of metastatic prostate cancer (LoMP) registry","volume":"29","author":"Lumen","year":"2021","journal-title":"European Urol Open Sci"},{"key":"R15-20260709","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1756-8722-7-20","article-title":"Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer","volume":"7","author":"Thalgott","year":"2014","journal-title":"J Hematol Oncol"},{"key":"R16-20260709","doi-asserted-by":"crossref","first-page":"3042\u201350","DOI":"10.1200\/JCO.20.00315","article-title":"Cancer and leukemia group B 90203 (Alliance): radical prostatectomy with or without neoadjuvant chemohormonal therapy in localized, high-risk prostate cancer","volume":"38","author":"Eastham","year":"2020","journal-title":"J Clin Oncol"},{"key":"R17-20260709","doi-asserted-by":"crossref","first-page":"648\u201355","DOI":"10.1097\/JU.0000000000003876","article-title":"A prospective randomized trial of neoadjuvant chemohormonal therapy vs hormonal therapy in locally advanced prostate cancer treated by radical prostatectomy","volume":"211","author":"Qian","year":"2024","journal-title":"J Urol"},{"key":"R18-20260709","doi-asserted-by":"crossref","first-page":"991\u201398","DOI":"10.1016\/j.urolonc.2019.07.009","article-title":"Neoadjuvant chemohormonal therapy combined with radical prostatectomy and extended PLND for very high risk locally advanced prostate cancer: a retrospective comparative study","volume":"37","author":"Pan","year":"2019","journal-title":"Urol Oncol"},{"key":"R19-20260709","doi-asserted-by":"crossref","first-page":"101\u201306","DOI":"10.1007\/s12262-022-03401-8","article-title":"Neoadjuvant therapy for locally advanced or oligometastatic prostate cancer: a retrospective comparative single-center study","volume":"85","author":"Wang","year":"2023","journal-title":"Indian J Surg"},{"key":"R20-20260709","doi-asserted-by":"crossref","first-page":"737\u201346","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"New Engl J Med"}],"container-title":["International Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000005040","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T10:00:42Z","timestamp":1783591242000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000005040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/js9.0000000000005040","relation":{},"ISSN":["1743-9159"],"issn-type":[{"value":"1743-9159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]},"assertion":[{"value":"2025-09-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}